(486b) In Vitro and in Vivo Validation of a New Drug Delivery System for Human LUNG Cancer

Eva M. Martín del Valle^*, José V. Román, Miguel A. Galán

Department of Chemical Engineering, University of   Salamanca, SPAIN

*Corresponding author: emvalle@usal.es

Human lung cancer is the main cancer cause of death in men and the third cancer cause in women. As it is well-known, current antitumor treatments involve chemotherapy which in most cases entails aggressive side effects.

In this respect, in this work we will present a new targeted drug delivery system, based on double functionalized microcapsules and its validation in vitro an in animal models for human lung cancer treatment. These microcapsules, produced using a fan jet nozzle, could be used in order to avoid the side effects of chemotherapy. It was shown that these microcapsules, used in situ tumor place, are biodegradable and biocompatible.

In order to validate the formulation, the in vitro effectiveness is tested by the MTT assay which measures the decrease of lived cells. The in vivo effectiveness is controlled by animal models with mice. Their tumor size is checked every day by palpation and possible damages in internal organs are analyzed by autopsy after the death of the animals. Autopsies and pathological anatomy tests were not shown metastasis in mice.

Cell experiments are carried out with the H460 line cell and the activity of bioconjugated antitumoral generally shows a faster effect of cell mortality and better behavior compared to the free administration solution of the drug.

The animal experiments present a good survival for mice with microcapsules therapy and an important advantage compared to non treated animals and even to animals treated with a free administration solution of the drug.

As a result, this study reports the preparation and in vitro/in vivo validation of an advanced drug delivery system, which in the future will enable clinical trials in humans.